iTeos Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
iTeos Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q2 2024.
  • iTeos Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$7.13M, a 79.2% increase year-over-year.
  • iTeos Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$108M, a 281% decline year-over-year.
  • iTeos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$113M, a 217% decline from 2022.
  • iTeos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $96.7M, a 54.9% decline from 2021.
  • iTeos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was $215M.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$108M -$7.13M +$27.2M +79.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$135M -$38.2M -$22.7M -146% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-08
Q4 2023 -$113M -$30.6M -$51M -249% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-06
Q3 2023 -$61.6M -$32.2M -$33.2M -3353% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 -$28.4M -$34.3M -$39.9M -710% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $11.5M -$15.6M -$85.1M -122% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-08
Q4 2022 $96.7M $20.5M -$164M -88.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-06
Q3 2022 $261M $991K -$68.7M -98.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $330M $5.63M +$32.1M Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-07
Q1 2022 $298M $69.6M +$83.1M Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-07
Q4 2021 $215M $185M +$200M Oct 1, 2021 Dec 31, 2021 10-K 2024-03-06
Q3 2021 $14.7M $69.6M +$80.3M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$65.6M -$26.5M -$19.3M -267% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$46.3M -$13.5M -$8.29M -158% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$38M -$14.9M -$9.53M -177% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-23
Q3 2020 -$28.5M -$10.7M -$3.76M -54.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$24.7M -$7.2M -$1.45M -25.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$23.3M -$5.25M -$845K -19.2% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
Q4 2019 -$22.5M -$5.38M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-24
Q3 2019 -$6.92M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$5.76M Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-12
Q1 2019 -$4.4M Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.